PharmaResearch announced on the 8th that its operating profit for the second quarter of this year, based on consolidated financial statements, was provisionally recorded at 55.9 billion won, an increase of 81.7% from the same period last year.
Second-quarter revenue increased by 69.2% year-on-year to 140.6 billion won, while net profit rose 46.4% to 42 billion won.
PharmaResearch is a pharmaceutical bio company based on aesthetic medicine, known for its skin booster 'Rejuran,' also referred to as salmon injection. Its major products include medical devices for improving facial wrinkles such as Rejuran, Rejuviel, Conjuran, and Rejuran Cosmetic, as well as pharmaceuticals, cosmetics, and health functional foods.
In June, PharmaResearch announced plans to split its investment-affiliated holding company, PharmaResearch Holdings, and the newly established PharmaResearch, which oversees its existing aesthetic business, to pursue a re-listing. However, due to strong backlash from individual investors, the plan for the spin-off was completely withdrawn last month.